7 / 27
Brahmer J. et al. AACR 2017
7
Median OS (95% CI), mo
Overall (N = 129)
9.9 (7.8, 12.4)
100
80
60
40
20
0
0
1
2
3
4
5
6
7
8
129
49
27
20
17
16
3
1
0
Years
No. at Risk
OS (%)
1 y OS, 42%
2 y OS, 24%
3 y OS, 18%
5 y OS, 16%
a
There were 3 deaths between 3 and 5 years, all due to disease progression; 1 surviving patient was
censored for OS prior to 5 years (OS: 58.2+ months)
5-Year Estimates of OS
a
CA209-003 5-Year Update: Phase 1 Nivolumab in Advanced NSCLC